Introduction {#Sec1}
============

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by chronic and erosive poliarthritis caused by abnormal growth of sinovial tissue or pannus, and causes irreversible joint disability. It is the most common inflammatory arthritis, affecting from 0.5 to 1% of the general population worldwide, with a female/male ratio of 2.5:1. The disease may appear at any age, but it is most common among those aged from 40 to 70 years and its incidence increases with age \[[@CR1]\]. Apart from pain, RA is associated with reduction of functional capacity, and increased comorbidity and mortality \[[@CR2], [@CR3]\].

For decades, the diagnosis of RA has been primarily based on clinical manifestations. However, especially during the first few months of the disease, the 1987 revised criteria of the American College of Rheumatology (ACR) are rarely met \[[@CR4]\]. About one-third of the patients with persistent arthritis do not fulfill the classification criteria, so it is often difficult to diagnose RA in the very early stages of the disease \[[@CR5]\]. On the other hand, numerous studies have shown that substantial irreversible joint damage occurs within the first 2 years \[[@CR6], [@CR7]\]. In many cases, irreversible damage of the joint cartilage has already occurred by the time laboratory and radiological parameters have confirmed the clinical daignosis RA \[[@CR8]\].

Because of the highly variable and unpredictable course of the disease, current therapeutic strategies in RA are increasingly aggressive regimens early in the course of the disease. Therefore, diagnostic tests with high-specificity are desirable for deciding on the optimal treatment \[[@CR9]\].

So far, serological support in the diagnosis of RA was mainly based on the presence of rheumatoid factors (RF) \[[@CR10]\]. RF can be detected in up to 70--80% of RA patients \[[@CR11]\]. The ACR criteria for RA diagnosis include the presence of RF, a decision that has contributed to the widely routine use of this test as a diagnostic marker for RA in most clinical laboratories. However, these antibodies are not very specific for RA and can also be detected in other rheumatic diseases, infectious diseases, and even in 3--5% of apparently healthy individuals \[[@CR10], [@CR12]\].

In recent years, many studies on antibodies against cyclic citrullinated peptide (CCP) have demonstrated that these antibodies are highly specific and predictive for RA \[[@CR13]\] that they can be detected years before onset \[[@CR14]\], and also that they are associated with joint destruction \[[@CR15]\]. Furthermore, the presence or absence of these antibodies seems to be a stable trait \[[@CR16]\]. Anti-CCP antibodies are detected in SE-positive as well as in SE-negative RA patients. Carriership of SE alleles in RA is associated with the presence of anti-CCP antibodies \[[@CR17]\].

This article investigates the sensitivity and specificity of the anti-CCP antibody in RA and association of it antibody with disease activity and radiological findings.

Materials and methods {#Sec2}
=====================

This study was conducted in the outpatient rheumatology unit of the Karadeniz Technical University Medical Faculty, Türkiye. Forty women patients with RA (median age, 48.3 years, range 22--74) who met at least four 1987 American College of Rheumatology (ACR) criteria and 38 women patients with fibromyalgia (median age 44, range31--60), who were considered as control group, were included in this study. Serum samples were obtained from both patient groups with fibromyalgia and RA and were aliquoted and stored at −80°C until assayed. Additionally, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), disease activity score 28 (DAS), visual analog scala (VAS), and human leukocyte antigen (HLA) genotype were recorded in patients with rheumatoid arthritis. Hand radiographs were taken at the beginning of study and radiological assessment was performed by Larsen score.

Serum antibodies directed to the cyclic citrullinated peptide (anti-CCP) were assessed with a commercial enzyme-linked immunosorbent assay (ELISA), (Aida gmbh, Germany, RA/CP detect, Ref 10165) and it was considered as positive if the antibody titer was greater than 15 U/ml.

These results were analyzed by SPSS (version 11.5). Student's *t* test for continuous variables was used to examine the significance of differences between the different groups. Non-parametric Mann--Whitney test was used to compare non-paired sets. *P*-value less than 0.05 was regarded as significant. Correlation between variables was assessed by Spearman's correlation coefficient and Pearson correlation.

Results {#Sec3}
=======

The anti-CCP test demonstrated a specificity of 100% and sensitivity of 50% for RA when compared with controls. The sociodemographic and disease-related characteristics of the patient with rheumatoid arthritis were summarized in Table [1](#Tab1){ref-type="table"}. The mean ± SD age of the patients was 48.3 ± 12.8 years, and all of them were females. The most common treatments received included combination of methotrexate (MTX), sulfosalazine (SSZ) and deltacortril (DTC) (32.5%), followed by the combination of methotrexate and deltacortril (27.5%), sulfasalazine and deltacortril (17.5%), nonsteroidal anti-inflammatory drugs (17.5%) and MTX-hydroxychloroquine (HCQ) (5%). On average, disease duration (S.D.) was 6.8 ± (6.6) years. RF was positive in 26 (65%) patients and negative in 14 (35%) patients. The anti-CCP was positive in 20 (50%) patients and negative in 20 (50%) patients. The mean ± SD titer of the anti-CCP was 104.6 ± 132.2 U/ml. The distribution of anti-CCP titers was demonstrated in Fig. [1](#Fig1){ref-type="fig"}. HLA genotypes of the four patients could not be studied. Five (12.5%) patients were in remission. In five (12.5 %) patients, DAS 28 was low, in 20 patients it was median, and in ten patients severely active. Table 1Sociodemographic and disease related characteristics of 40 patients with rheumatoid arthritisCharacteristics Age, mean ± SD years48.3 ± 12.8 BMI, mean ± SD26.9 ± 4.4 Female40 (100) RF, mean ± SD103.5 ± 154 Anti-CCP, mean ± SD (U/ml)104.6 ± 132.2 DAS28, mean ± SD3.9 ± 1.3 Remission5 (12.5) Low activity5 (12.5) Median activity20 (50) High activity10 (25) Disease duration ± years6.8 ± 6.6 ESR, mean ± SD (mm/1st h)29.2 ± 22.9 RF26/40 (65) HLADR34/36 (11.1) HLADR410/36 (27.8) VAS, mean ± SD4.8 ± 1.7 CRP, mean ± SD (mg/l)1.9 ± 3.0Drug treatment MTX/DTC11 (27.5) SSZ/DTC7 (17.5) MTX/SS/DTC13 (32.5) MTX/HQC/DTC2 (5) NSAID7 (17.5)\* Except where indicated otherwise, values are the number (%)Fig. 1The disturbance of the titers of anti-CCP antibodies in control group and patients with RA

In 18/20 patients (90%) with anti-ccp positive and in 8/20 patients (40%) with anti-CCP negative, RF was positive and there were significant differences between anti-CCP positive and negative patients for rheumatoid factor (*P *\< 0.05) (Table [2](#Tab2){ref-type="table"}). The analysis of serological parameters of disease activity (ESR, CRP, DAS 28 and VAS) and disease duration between the anti-CCP positive and negative patients with rheumatoid arthritis showed no significant difference in any parameter (*P *\> 0.05). According to radiological assessment of hand radiography by Larsen score (0--100), there was no significant difference between the anti-CCP positive and negative patients with RA. However, the analysis of wrist radiography (0--5) between the anti-CCP positive and negative patients with RA showed significant difference with a higher score in anti-CCP positive patients (*P *\< 0.05) (Table [3](#Tab3){ref-type="table"}). There was also no significant correlation between anti-CCP antibody and ESR, CRP, VAS, DAS 28 or radiological assessment. A small but significant correlation was found between RF and anti-CCP antibody (*r* = 0.3, *P *= 0.02) (Table [4](#Tab4){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). Additionally, there was a significant correlation between DAS 28 and RF, ESR, CRP, VAS, radiological assessment of right wrist or left wrist (*r* = 0.3, *P *= 0.03; *r* = 0.6, *P *\< 0.005; *r* = 0.4, *P *\< 0.005; *r* = 0.7, *P *\< 0.005; *r* = 0.3, *P *= 0.03; *r* = 0.4, *P *= 0.02, respectively) (Table [5](#Tab5){ref-type="table"}). Table 2Difference in the serological parameter in the CCP-negative versus CCP-positive patients with RAAnti-CCP positive patients (*n* = 20)Anti-CCP negative patients (*n* = 20)*P*-valueAge47.2 ± 14.549.5 ± 110.593ESR25.9 ± 19.432.5 ± 260.373CRP1.5 ± 2.42.2 ± 3.70.440Disease duration7.4 ± 7.56.2 ± 5.70.614VAS5.1 ± 1.74.5 ± 1.60.313DAS284.1 ± 1.33.8 ± 1.40.459RF (+)18/20 (90)8/20 (40)0.001HLADR3 (+)1 /19 (5.3)3/19 (17.6)0.258HLADR4 (+)4 /15 (21.1)6/17 (35.3)0.341Table 3Difference in the radiologic assessment of hand and wrist by Larsen score in CCP-negative versus CCP-positive patients with RAAnti-CCP positive patients (*n* = 20)Anti-CCP negative patients (*n* = 20)*P*-valueRigt hand score, mean ± SD12.7 ± 8.48.2 ± 5.60.051Right wrist score, mean ± SD2.4 ± 1.51.4 ± 1.30.010Left hand score, mean ± SD11.2 ± 7.810.0 ± 7.60.362Left wrist score, mean ± SD2.3 ± 2.31.4 ± 1.30.044Table 4The correlation between anti-CCP and other parameters of disease activity*X* ± SDAnti-CCPESR29.2 ± 22.9*P *= 0.54*r* = −0.11CRP1.9 ± 3.0*P *= 0.46*r* = −0.1VAS4.8 ±  1.7*P *= 0.09*r* = −0.02DAS 283.9 ± 1.3*P *= 0.63*r* = 0.07Left hand8.9 ± 7.6*P *= 0.75*r* = 0.05Right hand8.1 ±  5.6*P *= 0.37*r* = 0.14Left wrist1.3 ± 1.2*P *= 0.49*r* = 0.11Right wrist1.3 ± 1.2*P *= 0.10*r* = 0.26RF103.4 ± 154.1*P *= 0.02*r* = 0.35Fig. 2The correlation between anti-CCP antibodies and RFTable 5The correlation of DAS-28 with other parameters of disease activity*X* ± SDDAS 28RF103.4 ± 154.1*P *= 0.03*r* = 0.3ESR29.2 ± 22.9*P *\< 0.005*r* = 0.6CRP1.9 ± 3.0*P *\< 0.005*r* = 0.4VAS4.8 ± 1.7*P *\< 0.005*r* = 0.7Right wrist1.3 ± 1.2*P *= 0.03*r* = 0.3Left wrist1.3 ± 1.2*P *= 0.02*r* = 0.4

Discussion {#Sec4}
==========

The modern trend of RA treatment has been changed to start treatment as early as possible, based on the concept that early control of inflammation results in reduced joint damage \[[@CR18]\]. It therefore is important to differentiate between RA and other forms of arthritis early after the onset of symptoms \[[@CR19], [@CR20]\]. Although the 1987 American College of Rheumatology classification criteria for RA \[[@CR4]\] are often used in clinical practice as diagnostic tool for RA, they are not very well suited for the diagnosis of early RA \[[@CR21]--[@CR23]\]. The ACR criteria rely heavily on the expression of clinical symptoms of RA, but in early RA these clinical parameters are often not (yet) manifest. Therefore, a specific and sensitive (serological) marker, which is present very early in the disease, is needed. Rheumatologists need to be able to target the use of potentially toxic and expensive drugs to those patients, where the benefits clearly outweigh the risks \[[@CR23], [@CR24]\]. Therefore a good marker should ideally be able to predict the erosive or nonerosive progression of the disease.

In patients with RA, we found a sensitivity of 50% and specificity of 100% for anti-CCP. Schellekens et al. \[[@CR25]\] reported that ELISA methods using the cyclic citrullinated peptide (CCP-ELISA), in a series of 149 RA and 312 control sera, had a diagnostic sensitivity of 48% for a specificity of 96%. Kroot et al. \[[@CR26]\] identified 66% positive RA serum samples with CCP-ELISA. Lee and Schur \[[@CR27]\] found a sensitivity of 66% and specificity of 90.4%. Dubucquoi et al. \[[@CR28]\] describe a sensitivity of 85% and a specificity of 90.9% for anti-CCP. Although the specificity of anti-CCP antibodies in RA is more than 90% in almost all reports, the prevalence (sensitivity) of the same antibodies ranges from 33 to 87.2%. Such a discrepancy in sensitivity might reflect different cutoff levels, racial and genetic backgrounds, as well as the differences of used antigens and detection techniques among reports \[[@CR29]\]. Another important point concerning the diagnostic value of CCP is that about 35--40% of the RF-negative RA patients score positively for anti-CCP. In our study, only 2/14 (14.3%) patients with RF-negative RA were positive for anti-CCP antibodies and 12/14 (85.7%) patients with RA were negative.

The value of anti-CCP antibodies and RF for predicting the outcome of RA, clinical signs of disease activity, and the severity of radiographic joint damage has been investigated recently. The studies by van Jaarsveld et al. \[[@CR30]\], Kroot et al. \[[@CR26]\] and Meyer et al. \[[@CR15]\], all support the thesis that RA patients, positive for CCP, develop significanly more radiological damage than CCP-negative patients. Lately, Visser et al. \[[@CR31]\] assessed a clinical prediction model in early RA patients for the three forms of arthritis outcome: self-limiting, persistent nonerosive and persistent erosive arthritis in which CCP was strongly associated with erosive arthritis, more than RF. Forslind et al. \[[@CR32]\] reported the role of Anti-CCP in the radiological outcome in 379 cases with early RA, and concluded that anti-CCP as well as the baseline Larsen score and ESR was an independent predictor of radiological damage and progression in multiple regression analysis. In our study, CCP positive patients had a higher radiological score than CCP negative patients for radiological assessment of wrist by Larsen method. However, there was no significant difference for radiological assessment of hand by Larsen score.

In addition to the predictive value of CCP concerning radiological damage, Kastbom et al. \[[@CR16]\] showed that CCP is good predictor of disease activity. CCP was even better than RF in predicting disease activity over 3 years after the diagnosis of recent onset of RA. Bas et al. showed an association of IgA RF and anti-CCP with clinical signs of disease activity \[[@CR33], [@CR34]\]. The high prevalance of anti-CCP in RA patients with extensive disease activity and severe radiological changes, and even more impressively in RA patients who are IgM-RF-negative, suggests that anti-CCP is more useful than the RF alone in the early prediction of disease outcome and disease activity. We found a significant correlation between DAS 28 and RF, ESR, CRP, VAS, radiological assessment of right wrist or left wrist.

There is extensive evidence for the association between certain frequently occurring HLA-DRB1 alleles, the so-called "shared epitope" (SE)-encoding alleles (DRB1\*0101, \*0102, \*0104, \*0401, \*0404, \*0405, \*0408, \*0413, \*0416, and \*1001), and susceptibility to RA \[[@CR35]\]. Recently, it has been reported that the combination of anti-CCP antibodies and HLA-DRB1 locus antigens is strongly associated with more severe disease progressions \[[@CR17], [@CR36]\]. Most recent analyses \[[@CR37]\] suggested that the primary association of SE alleles is with the development of erosions, especially in RF-negative individuals \[[@CR38], [@CR39]\].

In our study, we could not find correlation between anti-CCP antibody and the serological markers of disease activity (ESR, DAS 28, CRP). There was a small, but significant positive correlation with anti-CCP and RF. Furthermore, we could find no significant difference between anti-CCP negative and anti-CCP-positive patients comparing ESR, CRP, HLA genotype, DAS. However, there was a significant differences between anti-CCP (+) and anti-CCP (−) RA patients for RF.

In conclusion, early development of erosive disease in RA is associated with the presence of several autoantibodies and the IgM RF is stil mostly used as a screening marker in the diagnosis of RA. However, the anti-CCP antibody assays have a comparable sensitivity in the diagnosis of RA but a much higher specifity. Further research, however, will be necesssary to elucidate the exact mechanism and the significance of protein citrullination in etiopathogenesis of RA.
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